Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Seqirus
Age
0–3
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Individuals of 6 through 47 months of age on the day of informed consent.
Individuals whose parent(s)/Legally Acceptable Representative (LAR) have voluntarily given written informed consent after the nature of the study has been explained according to local regulatory requirements, prior to study entry.
Individuals who can comply with study procedures including follow-up
Individual is in generally good health as per the Investigator's medical judgement
You may not be if
Acute (severe) febrile illness
History of any anaphylaxis, serious vaccine reactions or hypersensitivity, including allergic reactions, to any component of vaccine or medical equipment whose use is foreseen in this study
A known history of Guillain-Barre Syndrome or other demyelinating diseases such as encephalomyelitis and transverse myelitis
Any other clinical condition that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subject due to participation in the study
Received influenza vaccination or has had documented influenza disease in the last 6 months prior to informed consent.
Clareo Health | Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
